Coronavirus

People with COVID-19 who were hospitalized had a slightly higher rate of death than those with influenza. However, there were considerably more severe COVID-19 cases than the flu, leading to a much higher number of overall deaths associated with SARS-CoV-2.

This study of health care access and affordability found adults with long COVID reported more unmet health care needs in the past 12 months.

Can anakinra reduce inflammation and the need for mechanical ventilation in patients with severe COVID-19 pneumonia?

A literature review found we lack a consistent definition of long COVID, which can lead to variance in if and how these patients are treated.

How likely is COVID-19 reinfection? A new study estimates the protection from past COVID-19 infection by variant and time since infection.

These maternal infections caused seizures, developmental delays, and other health issues in two newborns.

Simulations suggest deaths from COVID-19 could be cut in half if 80% of eligible patients took the antiviral therapy.

A retrospective study indicated higher rates of neurodevelopmental abnormalities in areas such as motor function and speech and language during the first year among babies born to women who had experienced a COVID-19 infection during pregnancy.

Vilobelimab (Gohibic) was granted Emergency Use Authorization to treat adults hospitalized with severe COVID-19 infection.

COVID-19 prevention practices such as masking, social distancing, and school closures lowered children’s exposures to circulating respiratory viruses and other environmental triggers of asthma.

A novel "antibody-mimetic" molecule administered intranasally in animal model prevented coronavirus infection from older, current and emerging variants.

These findings suggest the World Health Organization's definition of post-COVID-19 condition (long COVID) may be too broad.

Ensitrelvir is an investigational 3CL protease inhibitor that reduced COVID-19 illness duration by 1 day.

This study examined the impact of COVID-19 vaccination and infection on the risk of cardiac and all-cause mortality in young people aged 12-29 years.

Because trust in science predicts willingness to get a COVID-19 vaccine, the results of this study have significant public health consequences.

Early treatment with nirmatrelvir-ritonavir (Paxlovid) was associated with the greatest clinical benefit in reducing COVID-19 hospitalization and death.

The findings of this study are consistent with other findings that maternal viral infection during pregnancy increases the risk for neurodevelopmental morbidity in offspring.

When given within 5 days of COVID-19 symptoms, Paxlovid appeared to reduce risk for developing Post-COVID-19 Conditions (PCC).

A new study found negative expectations prior to COVID-19 vaccination were associated with more systemic adverse events in individuals receiving their second dose of a COVID-19 vaccine.

A midsized study demonstrated no therapeutic benefit to patients with mild-to-moderate COVID-19 taking this class of anthelmintics.

"Antibiotics can safely be withheld in most patients with viral respiratory infections,” these study authors wrote.

Risk factors for VTE among COVID-19 patients included age greater than 55 years, male gender, a history of thrombophilia, and obesity.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

A new study reveals how US states fared, and some of the underlying reasons why the pandemic has played out in vastly different ways.

A new study shows vaccination decreased the chances of developing the debilitating condition by nearly half.

Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.

Despite failing to meet primary trial endpoints, molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients.

Yesterday, the FDA took a major step toward officially approving Paxlovid. Catch up on this story and the other top COVID-19 news updates from the past week.

The FDA's Antimicrobial Drugs Advisory Committee recommended approving Pfizer’s New Drug Application for Paxlovid to treat mild-to-moderate COVID-19 in adults at high risk of severe or fatal disease progression.

These investigators concluded Omicron XBB.1.5 the most successful COVID-19 variant of its lineage.